Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544499 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
A Phase 3 study of Primary Immune Thrombocytopenia (ITP), sponsored by argenx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT06544499: Recruiting Phase 3 study of Primary Immune Thrombocytopenia (ITP), sponsored by argenx.
NCT06544499 is a Phase 3 study of Primary Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by argenx. The registered enrollment target is 69 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06544499, a Phase 3 study of Primary Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- OTHER Placebo IV
Study Locations (20)
California
- University of Southern California Norris Comprehensive Cancer Center - Los Angeles
- Sharp Memorial Hospital - Oceanside
North Carolina
- Duke University Medical Center - Durham
- Brody School of Medicine at East Carolina University - Greenville
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Ohio State University Hospital East - Columbus
Other
- Allgemeines Krankenhaus der Stadt Linz - Linz
- Ordensklinikum Linz GmbH Elisabethinen - Linz
Arizona
- Mayo Clinic Hospital Scottsdale - Phoenix
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
What NCT06544499 shows while recruiting
NCT06544499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Primary Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT06544499 names 20 study sites across 16 states, led by California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT06544499 about?
NCT06544499 is a clinical study titled "A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia". The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo I...
What is the current status of trial NCT06544499?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2024-10-18. Estimated completion is 2028-06.
What conditions does trial NCT06544499 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT06544499?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Placebo IV (OTHER).
Who is sponsoring clinical trial NCT06544499?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544499 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06544499's enrollment target sits among peer trials
69 1794th of 2000 higher than 205 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI